- Patent Title: Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer
-
Application No.: US15510586Application Date: 2015-09-09
-
Publication No.: US10266526B2Publication Date: 2019-04-23
- Inventor: Megan Alene Cloonan Foley , Kevin Wayne Kuntz , James Edward John Mills , Lorna Helen Mitchell , Michael John Munchhof , Darren Martin Harvey
- Applicant: EPIZYME, INC.
- Applicant Address: US MA Cambridge
- Assignee: EPIZYME, INC.
- Current Assignee: EPIZYME, INC.
- Current Assignee Address: US MA Cambridge
- Agency: Sterne, Kessler, Goldstein & Fox P.L.L.C.
- International Application: PCT/US2015/049221 WO 20150909
- International Announcement: WO2016/040505 WO 20160317
- Main IPC: A61K31/4192
- IPC: A61K31/4192 ; C07D249/04 ; C07D451/04 ; C07D213/81 ; C07D213/82 ; C07D231/14 ; C07D233/90 ; C07D401/12 ; C07D241/26 ; C07D261/10 ; C07D263/34 ; C07D275/03 ; C07D209/08 ; C07D277/56 ; C07C271/18 ; C07D205/04 ; C07D211/34 ; C07D237/24 ; C07D401/14 ; C07D403/12 ; C07D403/14 ; C07D413/12 ; C07D417/14
Abstract:
The present disclosure provides carboxamides and sulfonamides having Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A, Y, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
Public/Granted literature
- US20170355695A1 SMYD Inhibitors Public/Granted day:2017-12-14
Information query
